Alnylam Pharmaceuticals admitted defeat, for now, in a lawsuit in Delaware federal court that accused Moderna's blockbuster ...

Here, doctors explain which COVID-19 vaccine is better when comparing Moderna, Pfizer, and Novovax. Plus, the efficacy of ...

Moderna has been rebuked by regulators after offering children cash to test the Covid vaccine ...

Pfizer and its German partner BioNTech on Tuesday won their attempt to invalidate two of rival CureVac's patents at London's ...

Health care stocks underperformed the broader market in 2023, with many companies falling short of their profit targets, and ...

Low uptake in the RSV and COVID vaccine markets is not surprising, an analyst says, and could mean weak earnings for ...

Alnylam Pharmaceuticals has conceded that Moderna's products do not infringe on its patents, as a court ruling determined.

Shares of Moderna Inc. MRNA slid 1.42% to $60.20 Friday, on what proved to be an all-around great trading session for the ...

In fall and winter, COVID-19 transmission usually rises. LA County offers free boosters at county clinics and vaccination ...

Novavax's protein-based shot is an option for COVID vaccination this season, joining refreshed formulas from Moderna and ...

Moderna (MRNA) closed at $58.39 in the latest trading session, marking a -0.56% move from the prior day. The stock's performance was behind the S&P 500's daily gain of 0.97%. Elsewhere, the Dow saw an ...